原发性 FSGS 中的循环通透因子是否已被发现？
Has the circulating permeability factor in primary FSGS been found?
机构信息
Department of Medicine, University of Washington, Seattle, Washington 98195, USA.
出版信息
Kidney Int. 2013 Aug;84(2):235-8. doi: 10.1038/ki.2013.204.
Abstract
A circulating permeability factor has long been implicated in the pathogenesis of primary focal segmental glomerulosclerosis (FSGS). Evidence in animal models and now in several cohorts of patients with primary FSGS suggests a role for the soluble urokinase-type plasminogen activator receptor (suPAR) as a biomarker and perhaps as a contributing factor. Confirmation of these findings might lead to new diagnostic and therapeutic strategies for FSGS as well as a better understanding of podocyte dysfunction.
摘要
循环通透性因子在原发性局灶节段性肾小球硬化症（FSGS）的发病机制中一直受到牵连。动物模型和现在原发性 FSGS 的几个患者队列的证据表明，可溶性尿激酶型纤溶酶原激活物受体（suPAR）作为一种生物标志物，可能是一个致病因素。这些发现的证实可能会为 FSGS 带来新的诊断和治疗策略，以及对足细胞功能障碍的更好理解。
相似文献
1
Has the circulating permeability factor in primary FSGS been found?原发性 FSGS 中的循环通透因子是否已被发现？
Kidney Int. 2013 Aug;84(2):235-8. doi: 10.1038/ki.2013.204.
2
Primary and Recurrent Focal Segmental Glomerulosclerosis Closely Link to Serum Soluble Urokinase-type Plasminogen Activator Receptor Levels.原发性及复发性局灶节段性肾小球硬化与血清可溶性尿激酶型纤溶酶原激活物受体水平密切相关。
Transplant Proc. 2015 Jul-Aug;47(6):1760-5. doi: 10.1016/j.transproceed.2015.03.048.
3
[Value of soluble urokinase receptor serum levels in the differential diagnosis between idiopathic and secondary focal segmental glomerulosclerosis].[可溶性尿激酶受体血清水平在特发性与继发性局灶节段性肾小球硬化鉴别诊断中的价值]
Nefrologia. 2014;34(1):53-61. doi: 10.3265/Nefrologia.pre2013.Oct.12272.
4
Decreased glomerular filtration as the primary factor of elevated circulating suPAR levels in focal segmental glomerulosclerosis.肾小球滤过率降低是局灶节段性肾小球硬化症患者循环中可溶性尿激酶型纤溶酶原激活物受体（suPAR）水平升高的主要因素。
Pediatr Nephrol. 2014 Sep;29(9):1553-60. doi: 10.1007/s00467-014-2808-5. Epub 2014 Apr 6.
5
Are serum suPAR determinations by current ELISA methodology reliable diagnostic biomarkers for FSGS?目前的 ELISA 方法检测血清 suPAR 是否为 FSGS 的可靠诊断生物标志物？
Kidney Int. 2014 Mar;85(3):499-501. doi: 10.1038/ki.2013.549.
6
Relationship between serum soluble urokinase plasminogen activator receptor level and steroid responsiveness in FSGS.局灶节段性肾小球硬化症中血清可溶性尿激酶型纤溶酶原激活物受体水平与类固醇反应性的关系
Clin J Am Soc Nephrol. 2014 Nov 7;9(11):1903-11. doi: 10.2215/CJN.02370314. Epub 2014 Oct 15.
7
Diagnostic and Prognostic Value of Soluble Urokinase-type Plasminogen Activator Receptor (suPAR) in Focal Segmental Glomerulosclerosis and Impact of Detection Method.可溶性尿激酶型纤溶酶原激活物受体（suPAR）在局灶节段性肾小球硬化症中的诊断和预后价值及其检测方法的影响。
Sci Rep. 2019 Sep 24;9(1):13783. doi: 10.1038/s41598-019-50405-8.
8
Soluble Urokinase Receptors in Focal Segmental Glomerulosclerosis: A Review on the Scientific Point of View.局灶节段性肾小球硬化中的可溶性尿激酶受体：科学观点综述
J Immunol Res. 2016;2016:2068691. doi: 10.1155/2016/2068691. Epub 2016 Jul 18.
9
Serum soluble urokinase-type plasminogen activator receptor levels and idiopathic FSGS in children: a single-center report.血清可溶性尿激酶型纤溶酶原激活物受体水平与儿童特发性 FSGS：一项单中心报告。
Clin J Am Soc Nephrol. 2013 Aug;8(8):1304-11. doi: 10.2215/CJN.07680712. Epub 2013 Apr 25.
10
Identifying a potential biomarker for primary focal segmental glomerulosclerosis and its association with recurrence after transplantation.鉴定原发性局灶节段性肾小球硬化的潜在生物标志物及其与移植后复发的关系。
Clin Transplant. 2019 Mar;33(3):e13487. doi: 10.1111/ctr.13487. Epub 2019 Feb 21.
引用本文的文献
1
Rare heterozygous variants in paediatric steroid resistant nephrotic syndrome - a population-based analysis of their significance.儿科激素耐药性肾病综合征中罕见的杂合性变异 - 基于人群的意义分析。
Sci Rep. 2024 Aug 10;14(1):18568. doi: 10.1038/s41598-024-68837-2.
2
Circulating Permeability Factors in Focal Segmental Glomerulosclerosis: Detection.局灶节段性肾小球硬化症中的循环通透性因子：检测
Kidney Int Rep. 2022 Sep 20;7(12):2691-2703. doi: 10.1016/j.ekir.2022.09.014. eCollection 2022 Dec.
3
Ion channels and channelopathies in glomeruli.离子通道与肾小球中的通道病。
Physiol Rev. 2023 Jan 1;103(1):787-854. doi: 10.1152/physrev.00013.2022. Epub 2022 Aug 25.
4
Dent Disease Type 2 as a Cause of Focal Segmental Glomerulosclerosis in a 6-Year-Old Boy: A Case Report.2型丹特病致一名6岁男孩局灶节段性肾小球硬化：病例报告
Front Pediatr. 2020 Oct 28;8:583230. doi: 10.3389/fped.2020.583230. eCollection 2020.
5
Soluble CD40 ligand directly alters glomerular permeability and may act as a circulating permeability factor in FSGS.可溶性CD40配体可直接改变肾小球通透性，并可能在局灶节段性肾小球硬化中作为一种循环通透性因子发挥作用。
PLoS One. 2017 Nov 20;12(11):e0188045. doi: 10.1371/journal.pone.0188045. eCollection 2017.
6
A circulating permeability factor in focal segmental glomerulosclerosis: the hunt continues.局灶节段性肾小球硬化中的一种循环通透性因子：探寻仍在继续。
Clin Kidney J. 2015 Dec;8(6):708-15. doi: 10.1093/ckj/sfv090. Epub 2015 Sep 15.
7
Causes and pathogenesis of focal segmental glomerulosclerosis.局灶节段性肾小球硬化的病因及发病机制。
Nat Rev Nephrol. 2015 Feb;11(2):76-87. doi: 10.1038/nrneph.2014.216. Epub 2014 Dec 2.
8
Circulating suPAR levels are affected by glomerular filtration rate and proteinuria in primary and secondary glomerulonephritis.循环中可溶性尿激酶型纤溶酶原激活物受体（suPAR）水平受原发性和继发性肾小球肾炎中肾小球滤过率及蛋白尿的影响。
J Nephrol. 2015 Jun;28(3):299-305. doi: 10.1007/s40620-014-0137-1. Epub 2014 Sep 4.
9
The novel diagnostic biomarkers for focal segmental glomerulosclerosis.局灶节段性肾小球硬化的新型诊断生物标志物。
Int J Nephrol. 2014;2014:574261. doi: 10.1155/2014/574261. Epub 2014 Mar 26.
本文引用的文献
1
Plasma soluble urokinase receptor levels are increased but do not distinguish primary from secondary focal segmental glomerulosclerosis.血浆可溶性尿激酶受体水平升高，但不能区分原发性和继发性局灶节段性肾小球硬化症。
Kidney Int. 2013 Aug;84(2):366-72. doi: 10.1038/ki.2013.55. Epub 2013 Feb 27.
2
Transmission of glomerular permeability factor soluble urokinase plasminogen activator receptor (suPAR) from a mother to child.肾小球通透性因子可溶性尿激酶型纤溶酶原激活物受体（suPAR）从母亲到孩子的传递。
Am J Kidney Dis. 2013 Feb;61(2):352. doi: 10.1053/j.ajkd.2012.10.011. Epub 2012 Nov 20.
3
Circulating suPAR in two cohorts of primary FSGS.原发性 FSGS 两队列的循环 suPAR。
J Am Soc Nephrol. 2012 Dec;23(12):2051-9. doi: 10.1681/ASN.2012030302. Epub 2012 Nov 8.
4
Serum-soluble urokinase receptor concentration in primary FSGS.原发性局灶节段性肾小球硬化症患者血清可溶性尿激酶受体浓度
Kidney Int. 2012 May;81(10):1043-1044. doi: 10.1038/ki.2012.32.
5
Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis.循环尿激酶受体是局灶节段性肾小球硬化的病因。
Nat Med. 2011 Jul 31;17(8):952-60. doi: 10.1038/nm.2411.
6
Circulating permeability factors in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis.特发性肾病综合征和局灶节段性肾小球硬化症中的循环通透性因子。
Clin J Am Soc Nephrol. 2010 Nov;5(11):2115-21. doi: 10.2215/CJN.03800609. Epub 2010 Oct 21.
7
suPAR: the molecular crystal ball.可溶性尿激酶型纤溶酶原激活物受体：分子水晶球
Dis Markers. 2009;27(3):157-72. doi: 10.3233/DMA-2009-0657.
8
Modification of kidney barrier function by the urokinase receptor.尿激酶受体对肾脏屏障功能的调节
Nat Med. 2008 Jan;14(1):55-63. doi: 10.1038/nm1696. Epub 2007 Dec 16.
9
The soluble D2D3(88-274) fragment of the urokinase receptor inhibits monocyte chemotaxis and integrin-dependent cell adhesion.尿激酶受体的可溶性D2D3(88 - 274)片段可抑制单核细胞趋化性和整合素依赖性细胞黏附。
J Cell Sci. 2004 Jun 15;117(Pt 14):2909-16. doi: 10.1242/jcs.01149. Epub 2004 Jun 1.
Zotero 插件